Abstract:Iodine-131‑labeled monoiodohypericin (131I‑Hyp) is a necrosis avid compound used as a complementary anticancer agent. Herein, the biodistribution in rats with re-perfused partial liver infarction (RPLI) was used to estimate its human internal radiation dosimetry. Iodine-123‑labeled monoiodohypericin (123I-Hyp) as a safer surrogate for 131I-Hyp was prepared with iodogen as oxidant. Determination of radiochemical yield and purification was performed by high performance liquid chromatography (HPLC). To control aggregation, the formulation was macroscopically and microscopically examined. Biodistribution of 123I-Hyp was studied in RPLI rats (n=18) at 4, 24 and 48 h post-injection. Tissue gamma counting (TGC), autoradiography and histology were performed. Dosimetry of 131I-Hyp in hepatic necrosis and in normal human organs was estimated using biodistribution data of 123I-Hyp, the Organ Level Internal Dose Assessment/Exponential Modeling (OLINDA/EXM®), a sphere model and male and female phantoms. A radiochemical yield of 95% was achieved in labeling of 123I-Hyp with a radiochemical purity of 99% after HPLC purification. In the Hyp added formulation, no macroscopic but minimal microscopic aggregation was observed. By TGC, selective accumulation in hepatic infarction and low uptake in viable liver of 123I‑Hyp/Hyp were detected, as confirmed by autoradiography and histology. Significantly higher doses of 131I-Hyp were delivered to necrotic (276‑93,600 mGy/MBq) than to viable (4.2 mGy/MBq) liver (P<0.05). In normal organs, 123I‑Hyp was eliminated within 24 h except for relatively high levels in the lungs and thyroid. Hepatobiliary elimination was a major pathway of 123I-Hyp causing high activity in the intestines. For both genders, dosimetry showed the longest residence time of 131I-Hyp in the remainder, followed by the lungs, intestines and thyroid. The highest absorbed radiation dose was seen in necrotic tissues and the shortest residence times and lowest absorbed radiation dose were found in the brain. 131I-Hyp selectively delivers higher radiation dose to necrosis compared with the rest of the body. Among normal organs, thyroids, lungs and intestines receive considerable radiation dose, which deserves cautious attention in developing this anticancer approach.

Targetability and biodistribution of radioiodinated hypericin: comparison between microdosing and carrier-added preparations

Biodistribution and radiation dosimetry of radioiodinated hypericin as a cancer therapeutic

Radioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation

Necrosis affinity evaluation of 131I-hypericin in a rat model of induced necrosis.

Biodistribution and anti-tumor efficacy of intratumorally injected necrosis-avid theranostic agent radioiodinated hypericin in rodent tumor models

Improvement of solubility and targetability of radioiodinated hypericin by using sodium cholate based solvent in rat models of necrosis.

Evaluation of hypericin: effect of aggregation on targeting biodistribution

Radiopharmaceutical evaluation of (131)I-protohypericin as a necrosis avid compound.

First Preclinical Evaluation of Mono-[ 123 I]iodohypericin As a Necrosis-Avid Tracer Agent

Synthesis and Preclinical Evaluation of Radioiodinated Hypericin Dicarboxylic Acid As A Necrosis Avid Agent in Rat Models of Induced Hepatic, Muscular, and Myocardial Necroses

Biodistribution and tolerance of intravenous iodine-131-labelled hypericin in healthy dogs

Preparation and validation of cyclodextrin-based excipients for radioiodinated hypericin applied in a targeted cancer radiotherapy

Sodium cholate, a solubilizing agent for the necrosis avid radioiodinated hypericin in rabbits with acute myocardial infarction

Pretargeting of necrotic tumors with biotinylated hypericin using 123I-labeled avidin: evaluation of a two-step strategy

Biodegradable hypericin-containing nanoparticles for necrosis targeting and fluorescence imaging.

Improved therapeutic outcomes of thermal ablation on rat orthotopic liver allograft sarcoma models by radioiodinated hypericin induced necrosis targeted radiotherapy

Effects of Skeleton Structure on Necrosis Targeting and Clearance Properties of Radioiodinated Dianthrones.

Necrosis Avidity: A Newly Discovered Feature of Hypericin and Its Preclinical Applications in Necrosis Imaging

Radioiodinated Hypericin Disulfonic Acid Sodium Salts As a DNA-binding Probe for Early Imaging of Necrotic Myocardium.

Tumor necrosis targeted radiotherapy of non-small cell lung cancer using radioiodinated protohypericin in a mouse model

Evaluation of Tumor Vascular Targeting Agents Labelled with 131I in Imaging of Tumor